The effect of alendronate, risedronate, and raloxifene on renal functions, based on the cockcroft and gault method, in postmenopausal women

Renal Failure

Volumn 29, Issue 4, 2007, Pages 471-476

  Yanik, Burcu ^a,c   Bavbek, Nükhet ^a   Yanǧk, Tuira ^b   Inegöl, Ilknur ^a   Kanbay, Mehmet ^a   Turgut, Faruk Hilmi ^a   Uz, Ebru ^a   Akçay, Ali ^a  

^a FATIH UNIVERSITY   (Turkey)

^b GÜVEN HOSPITAL   (Turkey)

^c Neurology ^*  (Turkey)

Author keywords

Alendronate; Nephrotoxicity; Osteoporosis; Raloxifene; Risedronate

Indexed keywords

ALENDRONIC ACID; RALOXIFENE; RISEDRONIC ACID;

ADULT; AGED; ANAMNESIS; ARTICLE; BIOCHEMISTRY; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITOMETRY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMUR; FEMUR NECK; HUMAN; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; LUMBAR SPINE; MAJOR CLINICAL STUDY; NEPHROTOXICITY; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL EXAMINATION; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCREENING;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; C-REACTIVE PROTEIN; CALCIUM; ETIDRONIC ACID; FEMALE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PHOSPHORUS; RALOXIFENE; URIC ACID;

EID: 34248584951     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220701260776     Document Type: Article

References (45)

1. Consensus Development Conference. Diagnosis and treatment of osteoporosis. Am J Med 1993;94:646-650.
2. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21:115-137.
3. Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann Intern Med. 1999;130:897-904.
4. Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA. 1997;277:543-547.
5. Genant HK, Baylink DJ, Gallagher JC. Estrogens in the prevention of osteoporosis in postmenopausal women. Am J Obstet Gynecol. 1989;161:1842-1846.
6. Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol. 1990;76:290-295.
7. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O'Connell D, Cranney A. Metaanalyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23:529-539.
8. Raisz LG, Prestwood KM. Estrogen and the risk of fracture - new data, new questions. N Engl J Med. 1998;339:767-768.
9. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.
10. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
11. Nakamura T, Liu JL, Morii H, Huang QR, Zhu HM, Qu Y, Hamaya E, Thiebaud D. Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis. J Bone Miner Metab. 2006;24(5):414-418.
12. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a three-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999 Aug 18;282(7):637-645.
13. Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin. 2005 Sep;21(9):1441-1452.
14. Bauss F, Russell RGG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int. 2004;15:423-433.
15. Fleisch H. Bisphosphonates in bone disease: from the laboratory to the patient, 4th ed. New York: Parthenon Publishing Group Ltd.;2000:1-212.
16. Green JR, Seltenmeyer Y, Jaeggi KA, et al. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol. 1997;80:225-230.
17. Troehler U, Bonjour J, Fleisch H. Renal transport of bisphosphonates: accumulation by renal cortical slices enhanced by calcium phosphate ions. J Lab Clin Med. 1985;106:23-29.
18. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377-387.
19. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735-1744.
20. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporosis Int. 1994;4:368-381.
21. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf. 1999;21:389-406.
22. Alden CL, Parker RD, Eastman DF. Development of an acute model for the study of chloromethane diphosphonate nephrotoxicity. Toxicol Pathol. 1989;17:27-32.
23. Pfister T, Atzpodien E, Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology. 2003;191:159-167.
24. Pfister T, Atzpodien E, Bohrmann B, et al. Acute nephrotoxicity of three intravenous bisphosphonates in the rat. Basic Clin Pharmacol Toxicol. 2005 Dec.;97(6):374-381.
25. Banerjee D, Asif A, Striker L, et al. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis. 2003;41:E18.
26. Lockridge L, Papac RJ, Perazella MA. Pamidronateassociated nephrotoxicity in a patient with Langerhans's histiocytosis. Am J Kidney Dis. 2002;40:E2.
27. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12:1164-1172.
28. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64:281-289.
29. Elomaa I, Kylmala T, Tammela T, et al. Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer. Int Urol Nephrol. 1992;24:159-166.
30. Jagdev SP, Purohit P, Heatley S, et al. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol. 2001;12:1433-1438.
31. Body JJ, Bergström B. Ibandronate is well-tolerated by 15-minute infusion in patients with metastatic bone disease from breast cancer and multiple myeloma. Breast Cancer Res Treat. 2004;88(Suppl. 1):135.
32. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003;14:1399-1405.
33. Body JJ, Pfister T, Bauss F. Preclinical perspectives on bisphosphonate renal safety. The Oncologist. 2005;10:3-7.
34. Bauss F, Body JJ. Ibandronate in metastatic bone disease: a review of preclinical data. Anticancer Drugs. 2005;16:107-118.
35. Von Moos R. Bisphosphonate treatment recommendations for oncologists. The Oncologist. 2005;10:19-24.
36. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005 Dec;20(12):2105-15. E-pub 2005 Aug 22.
37. Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab. 1998;83:1158-1162.
38. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
39. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2000;85:1895-1900.
40. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med. 1998;338:736-746.
41. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-1647.
42. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445-1451.
43. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002;287:847-857.
44. de Valk-de Roo GW, Stehouwer CD, Meijer P, Mijatovic V, Kluft C, Kenemans P, Cohen F, Watts S, Netelenbos C. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a two-year, placebo-controlled study. Arterioscler Thromb Vasc Biol. 1999;19:2993-3000.
45. Chin M, Isono M, Isshiki K, Araki S, Sugimoto T, Guo B, Sato H, Haneda M, Kashiwagi A, Koya D. Estrogen and raloxifene, a selective estrogen receptor modulator, ameliorate renal damage in db/db mice. Am J Pathol. 2005;166:1629-1636.